Breaking News Instant updates and real-time market news.

08:40
12/17/19
12/17
08:40
12/17/19
08:40

Week of 12/14 Redbook to be released at 08:55

TODAY'S FREE FLY STORIES

Hot Stocks
First Bancshares raises quarterly dividend to 10c from 8c per share » 20:54
01/21/20
01/21
20:54
01/21/20
20:54
FBMS

First Bancshares

$33.70 /

-0.4 (-1.17%)

The dividend is payable…

The dividend is payable on February 21, 2020 to shareholders of record as of the close of business on February 7, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
First Bancshares reports Q4 EPS 72c, consensus 74c » 20:54
01/21/20
01/21
20:54
01/21/20
20:54
FBMS

First Bancshares

$33.70 /

-0.4 (-1.17%)

Reports Q4 NII $33.8M vs.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
NanoViricides 2.5M share Secondary priced at $3.00 » 20:39
01/21/20
01/21
20:39
01/21/20
20:39
NNVC

NanoViricides

$8.10 /

+4.76 (+142.51%)

Aegis is acting as sole…

Aegis is acting as sole book running manager for the offering.

Earnings
Notable companies reporting before tomorrow's open » 20:25
01/21/20
01/21
20:25
01/21/20
20:25
ABT

Abbott

$89.76 /

+0.76 (+0.85%)

, BKR

Baker Hughes

$22.72 /

-0.9 (-3.81%)

, ALLY

Ally Financial

$30.25 /

-0.19 (-0.62%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Abbott (ABT), consensus 95c... Baker Hughes (BKR), consensus 31c... Ally Financial (ALLY), consensus 93c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Medtronic price target raised to $135 from $125 at Piper Sandler » 20:03
01/21/20
01/21
20:03
01/21/20
20:03
MDT

Medtronic

$120.30 /

+1.32 (+1.11%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
WellCare, Centene satisfy merger requirements » 19:49
01/21/20
01/21
19:49
01/21/20
19:49
CNC

Centene

$65.48 /

+0.96 (+1.49%)

, WCG

WellCare

$340.52 /

+3.55 (+1.05%)

Centene (CNC) and…

Centene (CNC) and WellCare (WCG) announced that they now have satisfied all regulatory requirements under the merger agreement to complete the pending transaction, including review by the U.S. Department of Justice. Subject to the satisfaction of customary closing conditions, the parties expect to close the transaction and the related divestitures of WellCare's Medicaid and Medicare Advantage plans in Missouri, WellCare's Medicaid plan in Nebraska and Centene's Medicaid and Medicare Advantage plans in Illinois on or about January 23, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Apple suppliers to start making new low-cost iPhone in February, Bloomberg says » 19:17
01/21/20
01/21
19:17
01/21/20
19:17
AAPL

Apple

$316.39 /

-2.27 (-0.71%)

, HNHPF

Hon Hai Precision

$0.00 /

+ (+0.00%)

Apple (AAPL) suppliers…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Ellington Financial 4.6M share Spot Secondary priced at $18.29 » 19:12
01/21/20
01/21
19:12
01/21/20
19:12
EFC

Ellington Financial

$18.85 /

+0.13 (+0.69%)

Morgan Stanley, Credit…

Morgan Stanley, Credit Suisse, BofA, UBS and Keefe Bruyette are acting as joint book running managers for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
Downgrade
Minerva SA downgraded to Sell from Neutral at Goldman Sachs » 18:59
01/21/20
01/21
18:59
01/21/20
18:59
MRVSY

Minerva SA

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Downgrade
Grupo Lala downgraded to Sell from Neutral at Goldman Sachs » 18:57
01/21/20
01/21
18:57
01/21/20
18:57
GRPBF

Grupo Lala

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia downgraded Grupo Lala to Sell from Neutral with a MXN 35.80 price target. The analyst is concerned that the company's slowdown in growth that started in the first half of 2019 will continue and margins will remain under pressure amid deteriorating margin conditions and waning impact from efficiency initiatives.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Compania Cervecerias downgraded to Neutral from Buy at Goldman Sachs » 18:53
01/21/20
01/21
18:53
01/21/20
18:53
CCU

Compania Cervecerias

$19.00 /

-0.33 (-1.71%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Grupo Lala upgraded to Buy from Neutral at Goldman Sachs » 18:50
01/21/20
01/21
18:50
01/21/20
18:50
GRPBF

Grupo Lala

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia upgraded Grupo Lala to Buy from Neutral with a MXN 25 price target. The analyst sees the stock valued attractively following the sell-off related to the company CEO departure and also believes that company may be an M&A target for larger multi-national players.

Upgrade
Gruma upgraded to Buy from Neutral at Goldman Sachs » 18:48
01/21/20
01/21
18:48
01/21/20
18:48
GPAGF

Gruma

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Coca-Cola Femsa upgraded to Buy from Neutral at Goldman Sachs » 18:47
01/21/20
01/21
18:47
01/21/20
18:47
KOF

Coca-Cola Femsa

$62.52 /

+0.41 (+0.66%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia upgraded Coca-Cola Femsa to Buy from Neutral with a MXN 149 price target. The analyst cites the company's stronger contribution from Brazil and a very attractive valuation.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Logitech CEO: We're growing all three of our businesses at a healthy clip » 18:46
01/21/20
01/21
18:46
01/21/20
18:46
LOGI

Logitech

$47.77 /

+1.2 (+2.58%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 18:44
01/21/20
01/21
18:44
01/21/20
18:44
NAVI

Navient

$13.86 /

-0.01 (-0.07%)

, IBM

IBM

$139.15 /

+0.84 (+0.61%)

, COF

Capital One

$102.29 /

-1.85 (-1.78%)

, FBK

FB Financial

$38.20 /

-0.66 (-1.70%)

, NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, MNLO

Menlo Therapeutics

$6.48 /

-0.17 (-2.56%)

, CIT

CIT Group

$45.23 /

-1.17 (-2.52%)

, SKT

Tanger Factory

$15.93 /

+0.56 (+3.64%)

, ETN

Eaton

$94.51 /

-1.19 (-1.24%)

, SUPN

Supernus

$24.70 /

+0.26 (+1.06%)

, ZION

Zions Bancorp

$49.93 /

-0.81 (-1.60%)

, IBKR

Interactive Brokers

$50.89 /

+0.7 (+1.39%)

, AMTD

TD Ameritrade

$50.76 /

+0.25 (+0.49%)

, FULT

Fulton Financial

$17.26 /

-0.07 (-0.40%)

, UAL

United Airlines

$85.84 /

-3.84 (-4.28%)

, ADAP

Adaptimmune

$4.14 /

-0.38 (-8.41%)

, BPMC

Blueprint Medicines

$79.69 /

-1.46 (-1.80%)

, ELAN

Elanco

$30.64 /

+0.65 (+2.17%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: Navient (NAVI) up 5.9%... IBM (IBM) up 3.8%... Capital One (COF) up 2.2%... FB Financial (FBK) up 2.0%... Netflix (NFLX) up 2.0%... ALSO HIGHER: Menlo Therapeutics (MNLO) up 7.4% after disclosing passive stake by Point72... CIT Group (CIT) up 5.8% after entering S&P MidCap 400 index... Tanger Factory (SKT) up 3.6% after entering S&P SmallCap 600 index... Eaton (ETN) up 2.0% after selling Hydraulics business for $3.3B... Supernus Pharma (SUPN) up 1.3% after FDA accepted SPN-812 NDA for review. DOWN AFTER EARNINGS: Zions Banc (ZION) down 1.7%... Interactive Brokers (IBKR) down 1.6%... TD Ameritrade (AMTD) down 1.5%... Fulton Financial (FULT) down 1.5%... United Airlines (UAL) down 0.2%... ALSO LOWER: Adaptimmune Therapeutics (ADAP) down 5.8% after equity offering... Blueprint Medicines (BPMC) down 5.3% after equity offering... Elanco (ELAN) down 2.3% after equity offering... Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
  • 23
    Jan
  • 23
    Jan
Hot Stocks
Supernus: FDA accepts for review NDA for SPN-812 » 18:35
01/21/20
01/21
18:35
01/21/20
18:35
SUPN

Supernus

$24.70 /

+0.26 (+1.06%)

Supernus announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says doesn't want to 'exploit' users with advertising » 18:31
01/21/20
01/21
18:31
01/21/20
18:31
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

Says mobile-only plans in…

Says mobile-only plans in Asia have added subscribers. Says wants to experiment with and test out yearly subscription plans. Says not integrating everybody's data. Says confident that best business model in the long-term is current model, as opposed to ad-based model. Says want to be a "safer" site where users can enjoy content. Says doesn't want to "exploit" users with advertising.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Costco CEO: We're a volume company, not a margin company » 18:25
01/21/20
01/21
18:25
01/21/20
18:25
COST

Costco

$313.28 /

+8.6 (+2.82%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says plans to increase content spending across the board » 18:24
01/21/20
01/21
18:24
01/21/20
18:24
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

Says plans to increase…

Says plans to increase content spending across the board. Says content spending to grow roughly 20% in 2020. Says "The Crown" viewership has been very "durable" in the U.K., U.S. and across the world. Says losing rights to sitcom "Friends" has had no impact on viewership. Says "The Witcher" delivered viewing hours for the company, says viewers "loved it" right away.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Petrobras says CARF issued 'unfavorable' decision on tax proceeding » 18:23
01/21/20
01/21
18:23
01/21/20
18:23
PBR

Petrobras

$14.76 /

-0.41 (-2.70%)

Petrobras said that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
First Midwest reports Q4 EPS 51c, consensus 50c » 18:15
01/21/20
01/21
18:15
01/21/20
18:15
FMBI

First Midwest

$21.58 /

-0.725 (-3.25%)

Reports Q4 revenue…

Reports Q4 revenue $194.9M, consensus $192.7M. Reports Q4 net interest margin 3.72% vs. 3.96% last year.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says Oscar-nominated original films 'very popular' with users as well » 18:14
01/21/20
01/21
18:14
01/21/20
18:14
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, DIS

Disney

$143.53 /

-0.72 (-0.50%)

Netflix (NFLX) says…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Medtronic: Trial shows 'superior' back pain relief with DTM SCS » 18:12
01/21/20
01/21
18:12
01/21/20
18:12
MDT

Medtronic

$120.30 /

+1.32 (+1.11%)

Medtronic announced…

Medtronic announced three-month results from a large, multicenter randomized controlled trial showing statistically significant and superior back pain relief with Differential Target Multiplexed Spinal Cord Stimulation compared to conventional SCS. Both arms used the Medtronic Intellis platform. Three-month results showed 80% of patients with chronic back pain treated with DTM reported at least 50% pain relief, compared with 51% of patients treated with conventional SCS, as measured by the Visual Analog Scale, a widely used and accepted measure for pain intensity. 50% pain relief, as measured by VAS, is a recognized industry standard to define minimum therapy success. The RCT demonstrated profound pain relief and significant reductions in back and leg pain with DTM. 63% patients with back pain treated with DTM reported profound pain relief of 80% or greater compared to 26% treated with conventional SCS. In aggregate, patients treated with DTM reported an average of 74% reduction in back pain compared to 46% with conventional SCS at three months. Similarly, improvements were observed with DTM for leg pain with a mean reduction of 72% compared to 59% with conventional SCS. The RCT results reported are from 94 implanted SCS patients who were randomized to either the treatment or control arm and followed over the course of three months. With these results the study met its primary endpoint of noninferiority compared with conventional SCS, and a pre-specified secondary statistical test for superiority showing the difference between DTM and conventional SCS as highly significant. The study will continue to follow patients through 12 months post implant. Medtronic acquired DTM therapy as part of its acquisition of Stimgenics announced in early January. DTM therapy, which was proven through the RCT only on the Medtronic Intellis platform, is a new and unique programming option available to treat patients with chronic pain that is based on years of preclinical research.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says seasonality from Q1 to Q2 likely to be 'more balanced' » 18:07
01/21/20
01/21
18:07
01/21/20
18:07
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, DIS

Disney

$143.53 /

-0.72 (-0.50%)

, GOOG

Alphabet

$1,484.92 /

+4.64 (+0.31%)

, GOOGL

Alphabet Class A

$1,482.70 /

+3.58 (+0.24%)

Netflix (NFLX) says Q1…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.